文摘
To define prognostic factors for breast cancer patients with brain metastases, compare their clinical courses and prognoses according to breast cancer subtypes, and analyze the causes of death in such patients. We retrospectively analyzed 1,466 patients diagnosed with brain metastases between April 1, 2001 and December 31, 2012, from 24 institutions of the Japan Clinical Oncology Group. Overall, 1,256 patients with brain metastases were included. The median overall survival (OS) was 8.7?months (95?% confidence interval [CI] 7.8-.6?months). Univariate and multivariate analyses revealed that patients diagnosed with brain metastasis within 6?months of metastatic breast cancer diagnoses, asymptomatic brain disease, or HER2-positive/estrogen receptor-positive tumors had increased OS. Median OS after the development of brain metastases was 9.3?months (95?% CI 7.2-1.3) for the luminal type, 16.5?months (95?% CI 11.9-1.1) for the luminal-HER2 type, 11.5?months (95?% CI 9.1-3.8) for the HER2 type, and 4.9?months (95?% CI 3.9-.9) for the triple-negative type. Luminal-HER2 type patients had significantly longer OS than patients with the luminal type (hazard ratio [HR]?=?1.50, P?P?HER2-type patients (HR?=?1.19, P?=?0.117). The prognosis and clinical course of patients with brain metastasis from breast cancer before and after developing brain metastases vary according to subtype. Focusing on the subtypes of breast cancer can optimize the prevention, early detection, and improved treatment of brain metastases.